8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02509546

8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I/II trial studies the side effects and best dose of 8-chloro-adenosine and how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Drugs used in chemotherapy, such as 8-chloro-adenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Status: 
Recruiting
Study Date: 
Tue, 09/01/2015 to Sat, 09/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: 8-chloro-adenosine Given IV